These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15490430)

  • 21. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonparametric statistical methods for cost-effectiveness analyses.
    Dinh P; Zhou XH
    Biometrics; 2006 Jun; 62(2):576-88. PubMed ID: 16918923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bootstrap-type confidence intervals for quantiles of the survival distribution.
    Hutson AD
    Stat Med; 2001 Jun; 20(11):1693-702. PubMed ID: 11391696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.
    Briggs AH; Wonderling DE; Mooney CZ
    Health Econ; 1997; 6(4):327-40. PubMed ID: 9285227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonparametric inference for median costs with censored data.
    Zhao H; Zuo C; Chen S; Bang H
    Biometrics; 2012 Sep; 68(3):717-25. PubMed ID: 22364557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.
    Wang H; Zhao H
    Biometrics; 2006 Jun; 62(2):570-5. PubMed ID: 16918922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved confidence intervals for the sensitivity at a fixed level of specificity of a continuous-scale diagnostic test.
    Zhou XH; Qin G
    Stat Med; 2005 Feb; 24(3):465-77. PubMed ID: 15635678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parametric modelling of cost data in medical studies.
    Nixon RM; Thompson SG
    Stat Med; 2004 Apr; 23(8):1311-31. PubMed ID: 15083485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
    Gibler KB; Huskamp HA; Sabatine MS; Murphy SA; Cohen DJ; Cannon CP
    Crit Pathw Cardiol; 2010 Mar; 9(1):14-8. PubMed ID: 20215905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Confidence intervals for ratio of means of delta-lognormal distributions based on left-censored data with application to rainfall data in Thailand.
    Thangjai W; Niwitpong SA
    PeerJ; 2023; 11():e16397. PubMed ID: 38025676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
    Nixon RM; Wonderling D; Grieve RD
    Health Econ; 2010 Mar; 19(3):316-33. PubMed ID: 19378353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Confidence intervals for the mean of diagnostic test charge data containing zeros.
    Zhou XH; Tu W
    Biometrics; 2000 Dec; 56(4):1118-25. PubMed ID: 11129469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On estimating medical cost and incremental cost-effectiveness ratios with censored data.
    Zhao H; Tian L
    Biometrics; 2001 Dec; 57(4):1002-8. PubMed ID: 11764238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?
    Pullenayegum EM; Tarride JE; Xie F; Goeree R; Gerstein HC; O'Reilly D
    Value Health; 2010; 13(4):487-94. PubMed ID: 20230549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian cost-effectiveness analysis for censored data: an application to antiplatelet therapy.
    Wu DB; Tsai YW; Wen YW
    J Med Econ; 2012; 15(3):434-43. PubMed ID: 22196038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.
    Chaudhary MA; Stearns SC
    Stat Med; 1996 Jul; 15(13):1447-58. PubMed ID: 8841654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonparametric confidence intervals for the one- and two-sample problems.
    Zhou XH; Dinh P
    Biostatistics; 2005 Apr; 6(2):187-200. PubMed ID: 15772099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating incremental cost-effectiveness ratios and their confidence intervals with different terminating events for survival time and costs.
    Chen S; Zhao H
    Biostatistics; 2013 Jul; 14(3):422-32. PubMed ID: 23426525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A shared random effects model for censored medical costs and mortality.
    Liu L; Wolfe RA; Kalbfleisch JD
    Stat Med; 2007 Jan; 26(1):139-55. PubMed ID: 16526006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.